Welcome to our dedicated page for Alimera Sciences news (Ticker: ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.
Alimera Sciences, Inc. (NASDAQ: ALIM) is a leading global pharmaceutical company committed to advancing retinal health. Founded in June 2003, the company specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. Alimera's primary focus is on diseases affecting the retina, particularly those that are not well managed by current therapies. The company's flagship product, ILUVIEN, is a sustained-release intravitreal implant used for the treatment of diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) outside the U.S.
ILUVIEN utilizes CONTINUOUS MICRODOSING™ technology, releasing sub-microgram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months. This technology helps to reduce disease recurrence, thereby enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S. and multiple international markets, including 17 European countries, China, and regions in the Middle East.
Recently, Alimera announced positive data from several clinical studies, such as the PALADIN study, which evaluated the long-term safety of ILUVIEN in treating DME. The company also made headlines by completing enrollment for the Synchronicity Study, focusing on YUTIQ, another fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis.
Moreover, Alimera continues to expand its executive team to strengthen its financial and operational capabilities. Elliot Maltz, C.P.A., has been named as the new Chief Financial Officer to drive growth and improve cash flow. The company's European operations are managed through its subsidiary, Alimera Sciences Limited, based in London.
Financially, Alimera Sciences has shown robust growth. In Q4 2023, the company reported net revenues of $26.3 million, an 88% increase compared to the same period in 2022. For the full year 2023, net revenues were up 49% to $80.8 million. This growth is a testament to the successful commercialization of ILUVIEN and YUTIQ.
Looking ahead, Alimera aims to further its mission of being invaluable to patients, physicians, and partners concerned with retinal health. The company is actively involved in numerous clinical studies and regulatory efforts to expand the therapeutic indications for its products, ensuring continued innovation and improved patient outcomes.
For more information, please visit www.alimerasciences.com.
Alimera Sciences (NASDAQ: ALIM) has announced an exclusive license agreement with Ocumension Therapeutics for its ILUVIEN® product, aimed at treating diabetic macular edema. The deal includes a $10 million upfront payment and potential milestones of up to $89 million, strengthening Alimera's financial position. Ocumension also made a $10 million equity investment in Alimera, purchasing 1,144,945 shares at $8.73 each. This partnership enhances Alimera's geographic reach in Asia, where diabetes treatment needs are rising.
Alimera Sciences (Nasdaq: ALIM) announced that Rick Eiswirth, President and CEO, will present at the Zooming with LD Micro virtual conference on April 15, 2021, at 11:00 AM ET. The event will include a live Q&A session and offers registered investors opportunities for one-on-one meetings. Alimera focuses on developing prescription ophthalmic treatments for retinal diseases, addressing significant unmet medical needs in aging populations. For more details, visit www.alimerasciences.com.
Alimera Sciences (Nasdaq: ALIM) announced that its President and CEO, Rick Eiswirth, will present at the Benzinga Biotech Small Cap Conference on March 25, 2021, at 12:00 pm ET. The conference will take place from March 24-25, 2021. Investors can view Eiswirth's presentation after registration and request a 1x1 meeting. Alimera is focused on the development of ophthalmic pharmaceuticals for retinal diseases, addressing a significant need in an aging population. For more information, visit www.alimerasciences.com.
Alimera Sciences (Nasdaq: ALIM) announced significant progress in its global expansion strategy with ILUVIEN pricing published in Denmark and Luxembourg. The company received reimbursement approval for the prevention of relapse in non-infectious uveitis from Ireland's largest private health insurers, covering approximately 50% of the country’s covered lives. Despite challenges posed by the COVID-19 pandemic, Alimera reports a consistent positive reception from healthcare professionals regarding ILUVIEN's impact on patients.
Alimera Sciences, a pharmaceutical firm focusing on ophthalmology, announced that President and CEO Rick Eiswirth will present at the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. Investors can view his presentation on March 17 after registering for the conference. An archived replay will also be accessible on the conference website. Alimera is dedicated to addressing retinal diseases, which often lack effective treatments and significantly impact aging populations. For more information, visit www.alimerasciences.com.
Alimera Sciences (Nasdaq: ALIM) announces that its President and CEO, Rick Eiswirth, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand from March 9 at 7:00 am ET for 90 days. Investors can register for the conference to view the presentation and request one-on-one meetings with Mr. Eiswirth. Alimera focuses on developing prescription ophthalmology treatments for retinal diseases, addressing significant unmet needs in this area.
Alimera Sciences, Inc. (Nasdaq: ALIM) reported its financial results for Q4 and FY 2020, revealing consolidated net revenue of $13.8 million for Q4, a 10% increase from Q3 but a 20% decline from Q4 2019. The annual net revenue totaled $50.8 million, reflecting a 6% decrease from 2019. Net losses were $(1.0) million for Q4 and $(5.3) million for the year, compared to $0.5 million income and $(10.4) million loss in 2019, respectively. Adjusted EBITDA was $1.1 million for Q4, down from $2.6 million in Q4 2019, while international net revenue increased by 20% compared to 2019.
Alimera Sciences (NASDAQ: ALIM) has expanded the availability of its ILUVIEN therapy to Finland for treating diabetic macular edema (DME) and non-infectious posterior uveitis (NIPU). This launch marks a strategic step in Alimera's mission to provide long-term treatment solutions, now available in 13 countries. ILUVIEN offers sustained release for up to three years, contrasting with traditional short-term therapies requiring frequent injections. The therapy aims to improve vision while minimizing recurrence and treatment frequency.
Alimera Sciences, Inc. is set to report its fourth quarter and full year 2020 financial results on February 24, 2021, after the market closes. A conference call will take place on February 25, 2021, at 9:00 AM ET, to discuss the financial results and corporate developments. Participants can pre-register for the call or join via dial-in options. A replay will be available for those unable to attend the live session. Alimera focuses on prescription ophthalmic pharmaceuticals for retinal diseases, addressing significant unmet medical needs.
Alimera Sciences, a leader in ophthalmology treatments, announced CEO Rick Eiswirth will present at the Microcap Rodeo Winter Wonderland Conference from February 16-19, 2021. The live presentation is scheduled for February 16, 2021, at 1:00 PM ET and will include a Q&A session. After the live event, the presentation will be available on-demand. Additionally, one-on-one meetings will take place on February 18 and 19, 2021. Alimera focuses on developing treatments for retinal diseases, addressing unmet needs in an aging population.
FAQ
What is the current stock price of Alimera Sciences (ALIM)?
What is the market cap of Alimera Sciences (ALIM)?
What is Alimera Sciences, Inc. specialized in?
What is ILUVIEN?
Where is Alimera Sciences headquartered?
What are the latest financial results for Alimera Sciences?
Who is the new Chief Financial Officer of Alimera Sciences?
What recent clinical studies has Alimera Sciences completed?
In which regions is ILUVIEN approved?
What is the mission of Alimera Sciences?
What technology does ILUVIEN utilize?
Where can I find more information about Alimera Sciences?
